Business Club November 18th November 1，French Pharmaceutical Merchant Sai Funfei-Anwte announced，acquired Chinese pharmaceutical manufacturers and distributors Meihua Sunshi Group Company for 520.6 billion US dollars (about 3.473 billion yuan)。This is the largest M & A case in the history of foreign pharmaceutical giants to Chinese OTC (non -prescription drug) pharmaceutical companies。
The same day，Swiss Pharmaceutical Company Nicokin acquired the controlling equity of Guangzhou Tianpu, a private biopharmaceutical company in China for $ 210 million。November 3，Sanofi Avant again announced，Hangzhou Sanofi Minsheng Health Pharmaceutical Co., Ltd., a company established with Hangzhou Minsheng Pharmaceutical Co., Ltd.。
Yu Xiong, deputy dean of the Shanghai Medical Industry Research Institute, said，From the perspective of this year's market situation，The major pharmaceutical companies in the world have achieved general recovery。At the same time，They enter the Chinese market，Starting merger and reorganization of Chinese pharmaceutical companies。This has become one of the biggest features of the Chinese pharmaceutical market in 2010。
The hot Chinese pharmaceutical market is attracting everyone's attention。"The compound annual growth rate of the Chinese pharmaceutical market in the next ten years will be 20%，By 2019, it will reach 4018.8 billion yuan，Become one of the most competitive markets in the world。"Lin Jianning, director of the Southern Medical Economics Research Institute of the State Food and Drug Administration, thinks，This also provides a logical background for why foreign giants are so rapidly deploying the Chinese pharmaceutical market。
It seems that Rui Guozhong, Secretary -General of the China Pharmaceutical Industry Technology Alliance，"The" Golden Ten Years "just opened is a process of reconstruction and concentration of the Chinese pharmaceutical industry，The result must be concentration improvement and industrial multi -polarization。"He told this newspaper reporter，"M & A is the fastest for industrial reconstruction and towards concentration、The most mainstream path，From this, the third round of stake betting appmergers and acquisitions of the Chinese pharmaceutical industry will be opened，That is the era of mergers and acquisitions。”
Stake Sports Betting
Yu Xiong, Shanghai Medical Work Institute, introduce to reporters，Among these stake betting appmergers and acquisitions of these more than 1 billion yuan，Products and markets are the two most important acquisition targets。"August this year，Nova acquired Aikang and received approval from the Ministry of Commerce of China，Nova acquired Aikang and received approval from the Ministry of Commerce of China，Novartis's global sales share will account for more than 50%，The share in the Chinese market is expected to reach more than 60%。”
This year's medical stake betting appmergers and acquisitions are not like before，All overseas pharmaceutical giants come to acquire a small pharmaceutical company in China，Instead, a successful case of Chinese -famous pharmaceutical companies acquired overseas assets。
November 9，China Hergele (Dalian) Pharmaceutical Co., Ltd. and Canada URO Technology Co., Ltd. officially signed a contract，M & A all its assets and technology，Become my country's first private enterprise to acquire foreign medical device companies。
The company's general manager Qin Yan said at the signing ceremony，The digital bladder monitoring system developed by the Canadian URO company is still technical blank in China，This merger will promote China's digital medical device products to enter the mainstream market in developed countries。
It is reported，This time, four companies in China and Canada participated in the acquisition of competition，Eventually from Hergeram victory。
Showing in the field of pharmaceutical business
2010，M & A and reorganization of the Chinese pharmaceutical industry is mainly concentrated in the field of pharmaceutical circulation。
Rui Guozhong pointed out to the Shanghai Securities News，With the acceleration of the concentration Stake Sports Bettingof pharmaceutical business，M & A and reorganization activities between companies will be more active。In the next 10 years，Chinese pharmaceutical business enterprises will be reduced from the current 12,000 to 2000。
At present，It is known as the most valuable medical business company in China-Nanjing Pharmaceutical，Vegetable eyes that have accumulated more attention。
Public information display，Nanjing State -owned Assets Supervision and Administration Commission 100%Holding Nanjing Pharmaceutical Industry (Group) Co., Ltd. (hereinafter referred to as "South Pharmaceutical Industry")，The latter 100%holds the largest shareholder of Nanjing Pharmaceutical Southeast Pharmaceutical Group，10 pharmaceutical companies under the South Pharmaceutical Industry，5 pharmaceutical business companies、More than 1,000 retail chain pharmacies，Except Nanjing Medicine，Also controlled a listed company -Jinling Pharmaceutical。As early as April this year，Nanjing Pharmaceutical or the news of reorganization will surface。
November 10，Nanjing pharmaceutical closing price is 15.04 yuan，Creating a new high within the year。The stock since the daily limit on October 28，The cumulative increase of the cumulative increase of nearly 30%in the later 10 trading days。During the period，About China Resources、Chinese Medicine Holdings、medicine、The four major pharmaceutical groups in the UK will participate in the news of Nanjing Pharmaceuticals.。
and the reporter learned，"2010-2015 National Medical Distribution Industry Development Plan" is expected to be introduced during stake sports betting appthe year，This plan points out the work focus of the medical circulation field during the "Twelfth Five -Year Plan" period: Encourage the merger and reorganization of drug distribution enterprises，Encourage the development of retail chain format，Cultivate national level、Local -level leading aircraft carrier enterprise。 (Source: Shanghai Securities News)
